Member Info for Greg25

Hi Guys,

There's always a risk as with every share. If you look back to the SFX-01 STEM primary endpoint results:

" Conclusive evidence of anti-cancer activity via objective responses (tumour shrinkage)"

"As expected SFX-01 had a favourable side effect profile, "

From this we can gather that SFX-01 represents a good form of Sulforaphane.

With substantial preclinical evidence that Sulforaphane will be positive in the SAH trials. The results are a guess but far more of an educated guess at this stage.

Also worth noting, the resolution passed at the recent AGM, could have been passed last year or the year before but I believe that it's been timed to coincide with these SAH results because it open the door for a co-investing partner/ merger to take place, Evgen has already stated they will be wanting $70M+ for that opportunity.

Exciting Times Ahead Here

A very rough calculation after SAH with Orphan Drug Status sales:

MCAP currently £23M

+$70M partner co-investor

+15% royalty from $500M sales $75M

Estimated MCAP £150M+

Commercial opportunity and monetisation
? Substantial market opportunity – CDK4/6i sales projected to reach c.$9bn by 2021e1
? Partner and/or co-develop SFX-01 as second-line therapy to CDK4/6i
? Up-front payment potential of c.$50m2 (although some deals e.g. AstraZeneca/Innate up-front of
$250m for antibody in combination with AZ’s immuno-oncology assets)
? Double digit royalties
? Partners – Big Pharma or large biotechs, opportunity to enhance existing second-line therapies
following CDK4/6i failure

Commercial opportunity and monetisation

? Estimated peak sales of $500m+ (c.f. $1.7bn for EG19621) as SAH orphan drug
? Partner and/or co-develop post-Phase IIb (2019) to fund pivotal Phase III
? Up-front payment potential post-Phase IIb of >$70m2 and post-Phase III of >$150m2
? Royalty rates estimated in high teens
? Broader deal for stroke increases value and bio-dollars
? Partners - companies interested in SAH/stroke or targeting Nrf2 pathway. Likely to be large
biotech or specialty pharma

Hi Headancer,

There's tonnes of research available to read up on, regarding Sulforaphane (SFN) and it's effect on the Nrf2 pathway with all the possible associated benefits from this.

Substantial preclinical evidence Of Sulforaphane.

SFX-01 is the only stable version of Sulforaphane.

From latest review paper:

"Evgen's principal investigator on the Company's Phase IIb trial in subarachnoid haemorrhage ("SAH") at University Hospital Southampton. The review details the different mechanisms of injury after SAH, summarises evidence that the Nrf2 pathway is active and protective after SAH and comments on the substantial preclinical evidence for the therapeutic potential of SFN as an Nrf2 activator."

Exciting Times Ahead Here

Good Luck All Shareholders

Hi Guys,

Big Pharmas, are going to be all over this, when the results are published.

Evgen Pharma has the worldwide rights to only stable version of Sulforaphane in SFX-01.

They have admitted to holding back the primary end results, to release the primary & secondary end point results together, just to maximize commercial value.

Evgen are clearly looking for a bidding war for SFX-01/ whole Company.

Exciting Times Ahead Here

Good Luck All Shareholders

Hi Guys,

Evgen Pharma has orphan drug status with SFX-01, so they can sell drug after Phase 2 results. SAH trial finishes in September with results soon after.

Exciting Times Ahead Here

Good Luck All Shareholders

Hi Guys,

Yes BTN-01 should be up and running by now, it's important to remember like BTN-14 will take time for the BOPD to come upto expected levels as they will effectively be flushing out the spoil from the workover. An update to say it's all in working order and the barrels of fluid per day has increased would be welcome, barrels of Oil per day next week or so .

Exciting Times Ahead Here

Good Luck All Shareholders

Oh I see, well that would be a first if the market share price reflected my confidence.

The market decides the share price, at where the share is priced at that moment in time.

We have around 6wks for the results of SAH trial of SFX-01, afterwards Evgen Pharma will be in a position to generate revenues, through orphan drug status. Which will reflect on the share price.

It's worth noting, the extra patent recently acquired, was to complete a circle so to speak.

Also noting, a resolution at the recent AGM, could well be looked upon as to clearing the pathway for a merger. Which again would reflect on the share price.

Exciting Times Ahead Here

Good Luck All Shareholders

Hi Radar,

Hope is for people sitting on a big loss. I'm not a day trader therefore I'm not concerned about the daily share price. I have built a large position here and I have no intention to sell before news. I am now going to watch other people buy, in the run up to news. Fully researched here and fully confident of rewards.

Exciting Times Ahead Here

Hi Guys,

We're getting exposure in the press, ADL are generating revenues which will increase next week.
https://twitter.com/AndalasEnergy/status/1162662832753827841?s=19

Good Luck All Shareholders

Yes I totally agree, there's a whole lot more to come here. The workover service agreement has been carefully constructed, to get ADL into a position with multiple entities (including CAV) and multiple projects in Indonesia.

Good Luck All Shareholders

Haha Don't listen to Doc and do some research instead. You'll find out they haven't met the criteria to increase the drawdown and they are now generating revenues.

The last CLN certainly didn't death spiral the share so what makes you think this one will.? If you actually know anything about that type of scenario you'll know generating revenues counter acts that scenario from happening.

Exciting Times Ahead Here

Revenues Are only going to increase here :)

Yes, there should be another RNS update next week with increased BOPD from BTN-01, with its larger pump fitted and work removing the scale.

Exciting Times Ahead Here

Increased Revenues with More to come.

Only 99% watercut when the well started as it was flushing through. 450bofpd - 99% = 4.5bopd.

Now we are getting 30bopd.

The bottom line is ADL are delivering now. BTN-14 water cut is 93.3% at 450 bofpd, (the same cut when it was 300) they are already above expectations and are looking to increase bofpd to 600, which should produce around 40bopd (double the previous). ADL will be firmly generating revenues from now on

Exciting Times Ahead Here

Your having a bad day pal.

The experience is a reference to Greg Malwhinney, he spent over a decade working in the oil & gas industry in Indonesia. The guy has a wealth of experience over 40yrs worth. Now he has Demi- God status.

"strategic partner experienced in oil and gas in Indonesia to work and coinvest with us in optimising production from Betun and developing the Selo field. We are also excited by the possibility of working with a strategic partner on other similar projects in Indonesia."

Exciting Times Ahead Her

Doubleup;

"Hendrik Kolonas, President Commissioner and CEO of PT Celebes Artha Ventura said: "We are very pleased to invite Andalas Energy & Power to support us in the development of the Betun-Selo KSO. For some time we have been looking for a strategic partner experienced in oil and gas in Indonesia to work and coinvest with us in optimising production from Betun and developing the Selo field."

Exciting Times Ahead Here.

Hi Guys,

Great RNS and I'm sure CAV our co-investor friends will be extremely happy too.

Exciting Times Ahead Here.

This is not CEB and the lies that came with that company.
I always research well it has developed since my investment though, originally I was told that an offer was put towards the bod and it turned out that Simon Gorringe had other plans, trying to work out what them other plans were was exciting, they always had Colter & Eagle Gas to fall back on, I didn't see any poster mention Indonesia again, so it stumped us all with them doing a workover and having CAV as a partner .

You seem to have a problem with someone being positive about a stock they're invested in , that seems bizarre to me as I wouldn't invest in a share I'm negative about., I'm always glass half full.

Exciting Times Ahead Here